IMTXHealthcare · BiotechnologyIMTX Stock Forecast: Immatics NV Price Predictions for 2026-2027
The 8 Wall Street analysts covering Immatics NV hold a median 12-month price target of $18 — +85.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 15 Aug 2026 — in the upper half.
IMTX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Immatics NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (72): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
IMTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IMTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +85.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 May 2026 | Chardan Capital | Maintains | Buy | $25 |
| 28 Apr 2026 | TD Cowen | Initiates | Buy | — |
| 16 Mar 2026 | Jefferies | Assumes | Buy | $18 |
| 24 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 19 Nov 2025 | Mizuho | Maintains | Outperform | — |
| 18 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 18 Sept 2025 | Guggenheim | Initiates | Buy | — |
| 28 May 2025 | Deutsche Bank | Initiates | Buy | — |
| 1 Apr 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 19 Nov 2024 | B of A Securities | Maintains | Buy | — |
| 7 Oct 2024 | Piper Sandler | Initiates | Overweight | — |
| 9 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 5 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 16 May 2024 | Mizuho | Maintains | Buy | — |
| 2 Nov 2023 | Cantor Fitzgerald | Initiates | Overweight | — |
| 31 Mar 2023 | Mizuho | Initiates | Buy | — |
| 23 Mar 2023 | Chardan Capital | Maintains | Buy | — |
| 10 Aug 2022 | Chardan Capital | Maintains | Buy | — |
| 3 June 2022 | SVB Leerink | Maintains | Outperform | — |
| 24 Mar 2022 | SVB Leerink | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMTX appears on the weeks it earns a place.
IMTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Immatics NV (IMTX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 26.8×
- Price / sales
- 34.6×
- Price / book
- 2.5×
- EV / EBITDA
- −4.3×
Cheaper than 30% of US stocks
Cheaper than 7% of US stocks
Cheaper than 41% of US stocks
Cheaper than 77% of US stocks
- Revenue growth (YoY)
- −59.0%
- Earnings growth (YoY)
- −59.0%
- Gross margin
- —
- Operating margin
- −867.9%
- Net margin
- 0.0%
Higher than 4% of US stocks
Higher than 8% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
- Return on equity
- −43.2%
- Return on assets
- −22.4%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
IMTX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Immatics NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about IMTX stock
What is the IMTX stock price forecast for 2026-2027?
The 8 Wall Street analysts covering Immatics NV have a median 12-month price target of $18, with estimates ranging from $12 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IMTX stock a buy right now?
Of the 8 analysts covering Immatics NV, 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immatics NV 57 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IMTX?
As at 15 Aug 2026, Immatics NV ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (72 of 100).
Will IMTX stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +85.4% from the last close, and Ticker Nerd's factor model ranks Immatics NV 57 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IMTX stock forecast for 2030?
No analyst covering Immatics NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $25 over the next 12 months.
How has IMTX stock performed over the past year?
Immatics NV returned +60.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Immatics NV do?
Immatics N.V. is a biotechnology company dedicated to the discovery and development of T-cell redirecting cancer immunotherapies.
About Immatics NV.
Immatics N.V. is a biotechnology company dedicated to the discovery and development of T-cell redirecting cancer immunotherapies. The company's primary function is to harness the power of the body's immune system to target and eliminate cancer cells, facilitating the development of personalized treatment approaches. Immatics is actively engaged in advancing its unique focus on cancer-specific targets and proprietary platforms, including Xpresident and ACTengine, which have been designed to identify and exploit tumor-specific targets. This company's work significantly impacts the biotechnology sector, particularly within oncology, where innovative therapies are continuously needed to address various cancer types. Immatics strives to bridge cutting-edge science with clinical application, playing a vital role in the medical R&D ecosystem. Headquartered in Tuebingen, Germany, with additional operations in Houston, Texas, Immatics represents a notable player in the intersection of biotechnology and immunotherapy, contributing pivotal advancements to the treatment of cancer and underscoring the momentum of precision medicine in the modern healthcare landscape.
CEO Dr. Harpreet Singh Ph.D. · 678 employees · Germany · https://www.immatics.com